Jardiance (Empagliflozin)

Jardiance is a widely prescribed prescription medication containing the active ingredient empagliflozin. It was developed through a strategic alliance between the German pharmaceutical giant Boehringer Ingelheim and the American company Eli Lilly and Company. Originally approved for the treatment of type 2 diabetes, its indications have expanded globally to include the treatment of heart failure and chronic kidney disease.

The manufacturing process for Jardiance is global, with primary production occurring in Germany (the home of Boehringer Ingelheim) and additional distribution and packaging across various regional hubs to meet local regulatory requirements. In the case of the Brazilian market shown in the image, the product is often imported or distributed via Boehringer Ingelheim's local legal entity in the country.

Ownership of the brand remains a shared commercial interest. While Boehringer Ingelheim is the primary developer and holder of many patents, the commercialization is a joint effort with Eli Lilly. Both companies are historic leaders in the metabolic health sector, with Boehringer Ingelheim being one of the world's largest private pharmaceutical companies, headquartered in Ingelheim am Rhein, Germany.